Evidence map›Paper›PMID 36437429›Full record

ArticlePflugers Archiv : European journal of physiology2023

FGF-23 protects cell function and viability in murine pancreatic islets challenged by glucolipotoxicity.

Betina Pajaziti, Kenneth Yosy, Olga V Steinberg, Martina Düfer

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pflugers Archiv : European journal of physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Fibroblast growth factor 23 as a risk factor for incident diabetes.Current opinion in nephrology and hypertension · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Betina PajazitiInstitute of Pharmaceutical and Medicinal Chemistry, Dept. of Pharmacology, University of Münster, Corrensstraße, 48, 48149, Münster, Germany.
Kenneth YosyInstitute of Pharmaceutical and Medicinal Chemistry, Dept. of Pharmacology, University of Münster, Corrensstraße, 48, 48149, Münster, Germany.
Olga V SteinbergInstitute of Pharmaceutical and Medicinal Chemistry, Dept. of Pharmacology, University of Münster, Corrensstraße, 48, 48149, Münster, Germany.
Martina DüferInstitute of Pharmaceutical and Medicinal Chemistry, Dept. of Pharmacology, University of Münster, Corrensstraße, 48, 48149, Münster, Germany. martina.duefer@uni-muenster.de.ORCID 0000-0003-1572-9235
University of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fibroblast growth factor FGF-23 is a member of the FGF-15/19 subfamily with hormonal functions. Besides its well-known role for bone mineralization, FGF-23 is discussed as a marker for cardiovascular disease. We investigated whether FGF-23 has any effects on the endocrine pancreas of mice by determining insulin secretion, electrical activity, intracellular Ca

Indexed as

Insulin-Secreting CellsIslets of LangerhansAnimalsApoptosisFibroblast Growth FactorsGlucoseInsulinInsulin SecretionMiceFibroblast Growth FactorsGlucoseInsulinBeta-cellCalcineurinFGF-23GlucolipotoxicityInsulinJNK

Identifiers

PMID36437429
PMCPMC9908675
OpenAlexW4310264354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.